What does a tesamorelin acetaat apotheek search actually specify chemically?
When a laboratory types tesamorelin acetaat apotheek, two different objects are being named at once. Acetaat denotes the acetate salt of the peptide. Apotheek denotes a pharmacy. A pharmacy listing, where a registered medicine exists, is built around a finished product: a trade name, a labelled quantity and a dispensing record. A research lot of tesamorelin acetate is built around a lyophilised peptide salt whose identity, chromatographic purity, counterion, water content and related-substance profile are tied to a single lot number on a certificate of analysis.
Tesamorelin is described in the drug-evaluation literature as a synthetic human growth hormone-releasing factor analogue (PMID:17086939). Independent reviews likewise classify it as a human growth hormone-releasing factor analogue and as a growth hormone-releasing factor analogue (PMID:19243281; PMID:22298602). Those classifications fix the chemical class—an N-terminally modified GHRH-length peptide—not a pharmacy category. They do not turn a research vial into a dispensed medicine, and they do not replace lot-specific HPLC and mass-spectrometric results.
For quality control, the acetate designation is an analytical specification. Solid-phase synthesis and reversed-phase purification in trifluoroacetic acid commonly leave TFA as the initial counterion. Conversion to acetate, residual TFA and the acetate assay therefore belong on the CoA if the material is offered as tesamorelin acetate. Net peptide content then corrects gross lyophilised mass for counterion and residual water so that gravimetric sample preparation is not biased.
Australian research supply should be judged as a documented reagent: structure or sequence identifier, lot number, HPLC purity with method conditions, intact mass, counterion, water, appearance, and a chromatogram that matches the lot. That package is not a pharmacy label. Groups arriving from an apotheek query still need those fields before the lot enters a characterisation workflow. A catalogue name without orthogonal data is not chemical identity, regardless of the language used in the search.
Which CoA identity fields replace a pharmacy product label?
A pharmacy label is not peptide identity testing. A research CoA for tesamorelin acetate should state the intended sequence or structure identifier, the salt form, the lot number, and the orthogonal results used to confirm that the principal HPLC peak is the intended analogue. Published summaries treat tesamorelin as a synthetic growth hormone-releasing factor analogue (PMID:21283099; PMID:17086939). The laboratory must show that the vial matches that chemical identity rather than inferring identity from a trade name.
Three concordant observations usually carry identity. Reversed-phase HPLC retention of the principal peak should fall within a predefined window relative to a qualified reference or a historical lot, under documented column, gradient, temperature and detection wavelength. Electrospray mass spectrometry should give a deconvoluted mass consistent with the intact N-hexenoyl 44-residue carboxamide, within a stated error window. The sample identifier on the chromatogram and the spectrum must match the vial lot; an unlinked typical figure is not lot evidence.
The N-terminal trans-3-hexenoyl group and the C-terminal amide are part of that identity. An unmodified GHRH(1-44) fragment, a des-hexenoyl species or a C-terminal acid is a different principal component even if area-percent purity looks high. Those species belong in the related-substance table. A CoA that reports only a single HPLC percentage, with no mass, no method and no lot-matched figure, cannot distinguish tesamorelin acetate from another long peptide that elutes as one ultraviolet peak.
Appearance of the lyophilised cake, behaviour in the HPLC diluent, and a statement of peptide content versus salt-and-water-inclusive mass complete the package. None of these fields is a dispensing record. They are what a research group should archive before using the lot as a characterisation standard or as a non-clinical test article. If any of the three identity observations is missing, the receiving laboratory should treat the lot as incompletely characterised until the gap is closed.
How should RP-HPLC related-substance profiling be documented for tesamorelin acetate?
Tesamorelin is a long, N-acylated peptide, so a single isocratic HPLC run is rarely sufficient for related-substance control. Typical research methods use reversed-phase HPLC on a wide-pore C18 or C4 column, a shallow acetonitrile gradient, and ultraviolet detection at a peptide-bond wavelength (commonly 214–220 nm), because aromatic content is modest and 280 nm is insensitive. The CoA should name the ion-pair reagent. Trifluoroacetic acid and formic acid change retention and can change apparent purity, so method identity includes the acid.
System suitability belongs in the batch record: tailing of the principal peak, plate count or peak width, resolution to the nearest specified impurity when a marker exists, and replicate peak-area precision. Integration rules—baseline type, tangent skim versus drop line—alter area-percent purity in a crowded envelope of deletion sequences and must be locked. Mobile-phase pH, column temperature and dwell volume should be recorded because they move relative retention of closely eluting deletion peptides.
Related substances that arise from this chemistry include truncated and deletion sequences, methionine oxidation where Met is present, asparagine or glutamine deamidation, residual des-hexenoyl peptide, and diastereomers from racemisation. Each species above a stated reporting threshold should appear as relative retention time and area percent. Area-normalised chromatographic purity is not an assay: it does not measure net peptide content and it ignores non-chromophoric counterions.
Diode-array peak-purity indices can flag co-elution but do not replace an orthogonal mass-spectrometric scan of the principal peak. For a 44-residue analogue, co-eluting deletion peptides of similar hydrophobicity are a realistic risk. A CoA that quotes one percentage without a peak table, method conditions or a lot-matched chromatogram cannot be compared with a later lot. Where a laboratory sets specification limits, those limits are protocol choices—principal-peak area-percent, largest unspecified impurity, total related substances—not pharmacy quantity statements.
What electrospray mass data confirm intact tesamorelin rather than a truncation?
Intact electrospray ionisation mass spectrometry is the practical identity method for this approximately 5 kDa analogue. Under acidic LC–MS conditions the peptide yields a charge-state envelope, commonly in the multiply charged region. Deconvolution should recover a mass consistent with the intact N-hexenoyl, C-terminally amidated 44-residue chain. The CoA should report observed mass, theoretical mass and the acceptance window appropriate to the analyser (a wider window on a unit-mass quadrupole; a tighter window on a high-resolution time-of-flight or orbital instrument).
The hexenoyl modification is a discrete mass increment relative to unmodified GHRH(1-44)-amide. A principal component whose mass matches the unmodified peptide, or matches a C-terminal acid rather than the amide, is not tesamorelin even if the HPLC trace looks clean. Sodium or potassium adducts should be recognised as adducts, not integrated as organic related substances.
Tandem MS, when provided, should include fragment ions that capture N-terminal hexenoyl-bearing pieces and C-terminal amide-containing pieces. Full peptide mapping is often absent from a commercial research CoA; if it is absent, the file should not claim sequence confirmation. Intact mass plus HPLC retention is identity-consistent; mapping is sequence-confirmed. Laboratory records should keep those phrases distinct. If only MALDI is supplied, the CoA should still state calibrant and whether the reported mass is protonated monoisotopic or average, because those choices change the acceptance window.
Related-substance spectra allow truncations and oxidations to be assigned by mass rather than by relative-retention folklore. Unidentified ultraviolet peaks should remain unidentified until a mass and a plausible assignment are attached. Literature classification of tesamorelin as a synthetic growth hormone-releasing factor analogue defines what the principal component ought to be (PMID:19243281; PMID:21283099); only the lot’s spectra show what was bottled. Calibration standard, resolution mode and whether the spectrum was averaged across the HPLC peak belong in the batch record so a later orthogonal check is comparable.
Why do acetate, residual TFA, water and net peptide content belong on the CoA?
The word acetaat in the trigger query is a salt-form claim. Tesamorelin acetate is a peptide salt. The lyophilised cake contains peptide, acetate, residual water and often residual trifluoroacetate carried from cleavage and purification. If a laboratory weighs cake and treats that mass as peptide, every calibration-curve concentration is biased. Acetate assay, residual TFA, Karl Fischer water and net peptide content are therefore quality attributes for any lot labelled acetate.
Acetate is typically determined by ion chromatography or by a validated HPLC method with ultraviolet or conductivity detection, reported as mass percent or as a molar ratio to peptide. Residual TFA, if reported, needs a method that distinguishes TFA from acetate. A lot labelled acetate that still carries a large TFA fraction is a mixed salt; it will not match a later acetate lot on a peptide-mass basis even when HPLC purity is identical. Residual solvents, if claimed on the CoA, should name the chromatographic method rather than appearing as an unexplained percentage.
Water by Karl Fischer, usually coulometric for small peptide samples, should be reported with sample size and on an as-is basis. Lyophilised peptides are hygroscopic; the CoA value is a snapshot for that closed presentation, not a constant after the stopper is removed.
Net peptide content is then stated so that peptide mass can be calculated from gross mass, or peptide content is reported from amino-acid analysis. Hydrolysis recovery of sensitive residues must be interpreted cautiously for a long analogue. The CoA should name the basis of the content figure: amino-acid analysis, nitrogen, or calculation from counterion, water and residual solvents. These figures are not pharmacy quantity statements. They are the arithmetic that lets two Australian research lots be compared on a peptide-mass basis. Laboratories that arrived via an apotheek search should still reject lots that omit counterion and water if the material will be used as a quantitative reference.
How do Australian research lots document tesamorelin acetate if they are not pharmacy-dispensed?
In Australia a research peptide supplier is not an apotheek. Research-grade tesamorelin acetate should be procured and archived as a laboratory reagent with lot traceability, not as a dispensed medicine. That distinction is the practical response to tesamorelin acetaat apotheek for groups that need the analogue as a characterised chemical.
A defensible pack includes a CoA whose lot number matches the vial; HPLC conditions and a lot-matched chromatogram; deconvoluted mass spectrometry; acetate, residual TFA and water; net peptide content and its basis; appearance; a laboratory handling statement for the lyophilised solid; and a packing list that ties vial count to the same lot. Tracked dispatch from local Australian stock, with the lot number on the consignment note, lets goods-inward staff reconcile vials with the CoA without treating the shipment as a pharmacy fill.
Receiving checks should be written as analytical tests: inspect seal and label concordance, record lot and retest date as documentation dates, file the chromatogram PDF, and, where the quality system requires it, run an identity spot-check of HPLC retention and intact mass against the CoA. Wrong salt form, missing hexenoyl mass increment, or a chromatogram that does not match the peak table is a non-conformance.
Supplier evaluation should privilege methods and limits over shop-front language. Phrases such as pharmaceutical grade and apotheek quality are undefined without chromatograms. HPLC purity, mass error, counterion, water and lot-matched figures are defined. ClaraScience supplies research-use-only materials, not pharmacy medicines; laboratories should keep that framing in inventory records so research lots are not mixed with clinical supply chains. Local stock and tracked dispatch also support audit trails: when the lot arrived, which CoA version applied, and which vials were opened for sample preparation. That chain is built from analytical documents rather than from a dispensing record.
Order Tesamorelin with documentation
If this guide helped you evaluate Tesamorelin for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Tesamorelin card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Is tesamorelin acetaat from an apotheek the same as a research acetate lot?
No. A pharmacy pathway, where it exists, supplies a finished medicine with dispensing documentation. A research lot is a peptide salt released against HPLC purity, mass-spectrometric identity, counterion and net peptide content for a named lot. ClaraScience materials are for laboratory research only and are not pharmacy medicines.
Which CoA fields must match the vial label?
The lot number, the product name including the acetate salt form, and the report identifier should match the vial label. Chromatogram headers and mass-spectrum sample names should repeat that lot. A generic figure that is not lot-linked does not support goods-inward identity. Mismatched identifiers are a receiving non-conformance.
Why does acetate versus trifluoroacetate change net peptide content?
Counterion mass is part of the lyophilised cake. An acetate-labelled lot that still contains unreported TFA is a mixed salt and will not match another acetate lot on a peptide-mass basis. A CoA should report acetate, residual TFA where relevant, Karl Fischer water, and the basis used to calculate net peptide content.
Are Australian research lots of tesamorelin acetate pharmacy-dispensed products?
No. Research-grade peptides supplied for laboratory characterisation are not dispensed medicines and should be inventoried as reagents. Laboratories should rely on lot CoAs, lot-matched chromatograms and tracked dispatch records, and should keep research inventory separate from any clinical supply chain.
What orthogonal tests support tesamorelin identity on a research CoA?
Reversed-phase HPLC retention of the principal peak under a documented method, plus electrospray mass spectrometry with a deconvoluted mass consistent with the intact N-hexenoyl 44-residue amide. Tandem fragment ions, when present, further support sequence-level assignment. Area-percent purity alone does not confirm identity.
What should goods-inward staff file for an Australian research shipment?
Reconcile tracked dispatch paperwork with vial lot and CoA, archive the lot-matched chromatogram and mass spectrum, and record any identity spot-check. Local stock and batch documentation provide the audit trail; the shipment is not a pharmacy fill.
References
- PMID:17086939 — Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor — Curr Opin Investig Drugs — 2006
- PMID:19243281 — Tesamorelin, a human growth hormone releasing factor analogue — Expert Opin Investig Drugs — 2009
- PMID:22298602 — Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Ann Pharmacother — 2012
- PMID:21283099 — Tesamorelin — Nat Rev Drug Discov — 2011
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
